NCT02927457View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 13, 2017

Primary Completion Date

June 12, 2018

Study Completion Date

June 12, 2018

Conditions
Lupus Erythematosus, Cutaneous
Interventions
DRUG

GSK2646264 1%

A cream for topical application with a concentration of 1% GSK2646264.

DRUG

Placebo

Subjects will receive matching Placebo topically.

Trial Locations (5)

10117

GSK Investigational Site, Berlin

42283

GSK Investigational Site, Wuppertal

48149

GSK Investigational Site, Münster

53127

GSK Investigational Site, Bonn

72076

GSK Investigational Site, Tübingen

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02927457 - Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects | Biotech Hunter | Biotech Hunter